Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment

Abstract

Background and ObjectivesOur objective was to investigate cellular and humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in a cohort of people with multiple sclerosis (pwMS) on pulsed B-cell–depleting treatment (BCDT). In particular, we intended to evaluate a possible association between immune responses and the timing of vaccination under BCDT.MethodsWe conducted a cross-sectional study among pwMS on pulsed BCDT or without disease-modifying treatment after completed SARS-CoV-2 vaccination. Samples were collected during routine clinical visits at the Multiple Sclerosis Center Dresden, Germany, between June 2021 and September 2021. Blood was analyzed for SARS-CoV-2 spike protein–specific antibodies and interferon-γ release of CD4 and CD8 T cells on stimulation with spike protein peptide pools. Lymphocyte subpopulations and total immunoglobulin levels in the blood were measured as part of clinical routine.ResultsWe included 160 pwMS in our analysis, comprising 133 pwMS on BCDT (n = 132 on ocrelizumab and n = 1 on rituximab) and 27 without disease-modifying treatment. Humoral and cellular anti–SARS-CoV-2 responses were reciprocally regulated by the time between the last BCDT cycle and vaccination. Although antibody responses increased with prolonged intervals between the last BCDT cycle and vaccination, CD4 and CD8 T-cell responses were higher in pwMS vaccinated at early time points after the last BCDT cycle compared with untreated pwMS. T-cellular vaccination responses correlated with total, CD3 CD4, and partly with CD3 CD8 lymphocyte counts. Humoral responses correlated with CD19 lymphocyte counts. Status post coronavirus disease 2019 infection led to significantly increased SARS-CoV-2–specific T-cell and antibody responses.DiscussionDelaying BCDT is currently discussed as a strategy to optimize humoral responses to SARS-CoV-2 vaccination. However, T cells represent an important line of defense against SARS-CoV-2 infection as well, especially in light of emerging variants of concern. We observed enhanced CD4 and CD8 T-cellular responses in pwMS receiving vaccination at early time points after their last BCDT cycle. These data may influence clinical decision making with respect to vaccination strategies in patients receiving BCDT.

Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients

“…Attempts to rectify the situation by using more-immunogenic vaccine platforms (e.g., mRNA and viral vector technologies), lowering rituximab dose, or giving additional vaccine doses have not shown promising benefits (32)(33)(34)(35)(36). Previous COVID-19 vaccine immunogenicity studies involving patients with systemic autoimmune diseases, multiple sclerosis, and lymphoma suggested that the key to successful COVID-19 vaccination among rituximab users is to extend the interval between rituximab treatment and vaccination (37)(38)(39). In keeping with the previous studies, we also found a positive correlation between the longer rituximab-to-vaccination intervals and the seroconversion probability of rituximab-exposed IMDD patients.…”

Three to four mRNA COVID‐19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization

“…Anti-CD20 extended interval dosing could be an opportunity to optimize the timing of the booster to target the period during which there could be B cell repopulation [31,32]. In our cohort, an association between the time of vaccination from the last anti-CD20 infusion or the CD19 + cell number and humoral vaccine response was not demonstrated, unlike other teams [33]. However, our population was very homogeneous because…”

Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study

“…However, some found suitable immunity after vaccination among rituximab-treated patients ( Takai et al, 2022 ). The protective response following SARS-CoV-2 in rituximab-treated patients is related to the interval between the last rituximab exposure and receiving the vaccine, rituximab concentration, and/or B cell counts in peripheral blood ( Ammitzbøll et al, 2022 ; Spiera et al, 2021 ; Takai et al, 2022 ; Woopen et al, 2022 ).…”